F. Staelens

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

H. Bliddal, J. Bijlsma, M. Østergaard, 2014, Annals of the rheumatic diseases.

FRI0246 Magnetic Resonance Imaging-Assessment of Early Response to Certolizumab Pegol in Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Phase Iiib Study Applying Magnetic Resonance Imaging at Weeks 0, 1, 2, 4, 8 and 16

L. Jacobsson, H. Bliddal, J. Bijlsma, 2014 .

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study

B. Haraoui, M. Khraishi, J. Syrotuik, 2019, Therapeutic advances in musculoskeletal disease.

Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial

A. Gottlieb, M. Lebwohl, K. Reich, 2021 .

SAT0126 Evaluation of two dosing regimens of certolizumab pegol for maintenance of clinical response in patients with active rheumatoid arthritis: Primary results from doseflex, a phase IIIB study

D. Furst, M. Greenwald, W. Koetse, 2013 .

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

B. Devellis, B. Gandek, R. Devellis, 2015, Arthritis care & research.